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Abstract: Series of twenty-five benzyl (2S)-2-(arylcarbamoyl)pyrrolidine-1-carboxylates was prepared
and completely characterized. All the compounds were tested for their in vitro ability to
inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), and the selectivity of
compounds to individual cholinesterases was determined. Screening of the cytotoxicity of all
the compounds was performed using a human monocytic leukaemia THP-1 cell line, and the
compounds demonstrated insignificant toxicity. All the compounds showed rather moderate
inhibitory effect against AChE; benzyl (2S)-2-[(2-chlorophenyl)carbamoyl]pyrrolidine-1-carboxylate
(IC50 = 46.35 µM) was the most potent agent. On the other hand, benzyl (2S)-2-[(4-bromophenyl)-] and
benzyl (2S)-2-[(2-bromophenyl)carbamoyl]pyrrolidine-1-carboxylates expressed anti-BChE activity
(IC50 = 28.21 and 27.38 µM, respectively) comparable with that of rivastigmine. The ortho-brominated
compound as well as benzyl (2S)-2-[(2-hydroxyphenyl)carbamoyl]pyrrolidine-1-carboxylate
demonstrated greater selectivity to BChE. The in silico characterization of the structure–inhibitory
potency for the set of proline-based carbamates considering electronic, steric and lipophilic properties
was provided using comparative molecular surface analysis (CoMSA) and principal component
analysis (PCA). Moreover, the systematic space inspection with splitting data into the training/test
subset was performed to monitor the statistical estimators performance in the effort to map the
probability-guided pharmacophore pattern. The comprehensive screening of the AChE/BChE profile
revealed potentially relevant structural and physicochemical features that might be essential for
mapping of the carbamates inhibition efficiency indicating qualitative variations exerted on the
reaction site by the substituent in the 3′-/4′-position of the phenyl ring. In addition, the investigation
was completed by a molecular docking study of recombinant human AChE.
Molecules 2017, 22, 1969; doi:10.3390/molecules22111969 www.mdpi.com/journal/molecules
Molecules 2017, 22, 1969 2 of 26
Keywords: proline; carbamates; in vitro cholinesterase inhibition; in vitro cytotoxicity assay; CoMSA;
IVE-PLS; molecular docking study
1. Introduction
An amide (–CONH–) and/or carbamate (–OCONH–) group is present in a number of clinically
used drugs [1] and pesticides [2]. Both terminations can be variously substituted, which results in
a privileged structural fragment [3,4]. These moieties interact with a number of enzymes/receptors
and, by means of these target sites, they are able to affect the biological response. Therefore, the reason
for the widespread occurrence of amides and carbamates among new biologically active compounds is
obvious [5–15]. Carbamate-like compounds can be considered as essential cholinesterase inhibitors
(ChEIs) [1,16–18]. Acetyl-(AChE, EC 3.1.1.7) and butyryl-cholinesterases (BChE, EC 3.1.1.8) are two
important cholinesterases (ChEs) that occur in the human body. ChEs belong to the group of serine
hydrolases [19]. The major role of AChE is to catalyse the hydrolysis of acetylcholine (ACh) in
cholinergic synapses, while BChE can hydrolyse ACh as well as other esters; nevertheless, it seems
its concentration in brain is especially important at Alzheimer’s disease (AD) [20,21]. The inhibition
of both enzymes causes an increase in the ACh concentration in cholinergic synapses and can
subsequently affect a number of pathogenic processes. ChEIs are used in the treatment of various
neuromuscular disorders and have provided the first generation of drugs for the treatment of
Alzheimer’s disease, myasthenia gravis and glaucoma. An increase in the concentration of ACh
can result in an alleviation of the symptoms of these diseases [22].
AD is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills,
and eventually the ability to carry out the simplest tasks [23]; moreover, the AD is the most common
cause of dementia among older adults. It can be stated that it is the most devastating central nervous
system disorder, especially in Western civilization. Worldwide, nearly 44 million people have AD or
related dementia, and more than 100 million people worldwide are estimated to be affected by AD by
2050 [24,25]. Although the etiology of the AD is not yet entirely known, several conditions are believed
to have important roles in the pathogenesis of this disease; they include aggregation and accumulation
of amyloid-β deposits, oxidative stress and low levels of ACh [26]. In the AD brain, AChE levels
decrease, while BChE levels are reportedly increased or unchanged, with changes becoming more
pronounced during the disease course. Strategies that increase the ACh level show symptomatic
efficacy in AD treatment [21]; therefore competitive ChEIs, such as galantamine and rivastigmine, as
well as non-competitive ChEIs tacrine and donepezil are clinically used for relieving AD. In addition,
memantine, a N-methyl-D-aspartate (NMDA) receptor antagonist, was also approved by the FDA for
relieving AD [25]. Thus, research of new ChEIs may be valuable for further progress in the treatment of
AD. Recently, new preferential or BChE selective inhibitors [26–28] as well as various multifunctional
anti-Alzheimer agents [29–32] were reported.
This is a follow-up paper to the paper devoted to recently reported carbamates as
potential ChEIs [16–18,33] and dealing with synthesis and ChE inhibiting properties of benzyl
(2S)-2-(arylcarbamoyl)pyrrolidine-1-carboxylates 1–9c. In the context of our previously described
N-heterocycles, simple modifications of proline, an atypical α-amino acid, were investigated.
The rational production of properties supported by computers is basically regarded as a preliminary
stage or an “intuitive roadmap” on the path from a hit to a drug candidate. A pool of
computer-assisted drug design (CADD) procedures, including multidimensional quantitative-structure
activity relationships (mD-QSAR), diffused quickly into computational medicinal chemistry getting
more and more popular in the rational drug discovery [34].
The in silico characterization of the structure–inhibitory potency for the set of proline-based
carbamates considering electronic, steric and lipophilic properties was provided using
comparative molecular surface analysis (CoMSA) and principal component analysis (PCA) [35].
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Moreover, the systematic space inspection with splitting data into the training/test subset was
performed to monitor the statistical estimators performance in the effort to map the probability-guided
pharmacophore pattern. Consequently, a pseudo-consensus 3D-QSAR approach was applied to
retrieve an “average” pharmacophore hypothesis by investigating the best models for training/test
subpopulations to specify the potentially important factors contributing to the inhibitory activity
of potential ChEIs. In addition, the investigation of these positional isomers of proline-based
carbamates was completed by a molecular docking study of recombinant human AChE (rhAChE).
Thus, the comprehensive screening of the AChE/BChE profile revealed the potentially relevant
structural and physicochemical features that might be essential for mapping of the carbamates
inhibition efficiency, indicating qualitative variations exerted on the reaction site by a substituent in
the 3′-/4′-position of the phenyl ring.
2. Results
2.1. Chemistry
From conventional and emerging chemical approaches for amide bond formation [3,36–40] and from
the methods which have been previously used in our laboratories [8,41–43], we have selected the procedure
where propylphosphonic anhydride (T3P) has been used as a coupling agent [43]. The application of
this one-pot reaction to commercially available (2S)-1-[(benzyloxy)carbonyl]-pyrrolidine-2-carboxylic acid
and a wide variety of substituted anilines led to the formation of corresponding substituted anilides 1–8c
(see Scheme 1) that were isolated in high yields and high purity.
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These standards were chosen because of their different structures. While rivastigmine is a classical
acylating pseudo-reversible carbamate ChEI that inhibits both AChE and BChE, galanthamine is
a non-acylating competitive reversible ChEI as well as an allosteric ligand at nicotinic ACh receptors.
The choice of these reference drugs with different mechanisms of action can provide relevant results.
The results are summarized in Table 1 and expressed as 50% inhibitory concentration (IC50 (µM)), or
the concentration of inhibitor required for 50% inhibition of the mentioned enzymes.
Table 1. Structures of discussed carbamates 1–9c; calculated values of lipophilicity (clogP), polar
surface area (PSA), polar volume (PV) and in vitro AChE and BChE inhibition (IC50) in comparison
with standards rivastigmine (RIV) and galanthamine (GLT) and in vitro cytotoxicity assay (IC50) of
compounds. ChE inhibitions are expressed as mean ± SD (n = 3 experiments).
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The principal aim of the ligand-based investigation was the comparative study of the molecular
surface using the CoMSA approach to mo l in vitro activity observed for a set of proline-based
carbamates as potential AChE/BCHE inhibitors. The findings of inhibiting potency modeling
(AChE and BChE) were co related with surf ce escriptors regard g multiple training/test subsets
and (in)dependent variables used, respectively. Unfortunately, the q2cv performance of AChE nd BChE
profile for the ntire proline-based c rbamates dataset 1–9c i the training ataset is not atisfactory
for CoMSA models (q2cv < 0.5), irrespective of the map size (20 × 20–50 × 50) or applied template
molecules 1 and 7a–c. Obviously, a model predictive power cannot be evaluated just by goodness
of data fitting with the cross-validated leave-one-out (CV–LOO) procedure [46]. Thus, the external
validation with splitting the molecule subset into a set of training/test collections was performed to
evaluate the model predictive ability with SDEP and q2test statistics as well. The CoMSA performance
for models divided arbitrarily into training/test subsets in 2:1 ratio (18/7) ranked according to the
molecule inhibitory activity (AChE and BChE), regarding ortho-, meta-, and para-substitution (or their
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combinations), indicated pretty poor model abilities accompanied with poor model predictive power.
Moreover, the Kennard–Stone procedure on dependent variables was applied to split representatively
the collection of data into training/test subsets, however the statistical characteristics of CoMSA
models for AChE/BChE was not noticeably improved.
The obtained findings confirmed that the separation of objects into training/test subgroups is
not a trivial issue. Hence, an additional assessment, namely Stochastic Model Validation (SMV),
has been performed as a kind of “perturbation” procedure to investigate the data structure [47].
Thus, the fluctuations of the statistical estimators during CoMSA AChE and BChE modeling were
scrutinized, as the original dataset of 25 molecules was recurrently sampled into 18/7 training/test
series (fraction 2/3 to 1/3). In this case, it was technically viable to investigate the entire pool of
systematically generated training/test populations (C825 ≈ 106). The observed profile for q2cv vs. q2test
distribution confirms the intuitive interpretation of q2cv/q2test fluctuation pattern, where the areas of
higher modeling ability within the training set can be depicted for AChE as well as BChE potency
(q2cv ≥ 0.75). On the other hand, the preferential choice of objects into the training set that easily
fit into the model is accompanied with the decline in the predictive performance for the remaining
ones, which confirms the dichotomic nature of q2cv/q2test parameters, where high value of q2cv does not
automatically imply a high model predictability [48]. It should be emphasized that the great advantage
of the QSAR/QSPR paradigm lies not in the extrapolation as stated Hansch [49].
Additionally, Figure 1a,b depicts the molecule selection frequency into the test subset
in the function of the compound number, while sampling the best models (q2cv ≥ 0.50).
Surprisingly, a relatively smooth compound distribution within the training/test subpopulations
is disrupted by outnumbering of molecules 8a–c for AChE vs. 1, 4–6c, 8a–c for BChE profile (common
compounds 8a–c). Generally speaking, the indicated molecules are mainly para-substituted isomers.
Interestingly, the BChE inhibitory activities for the positional isomers increase progressively and can be
ranked according to the rough relation, where ortho > meta > para, which partly explains the preferential
selection of para-positioned molecules into the test subset.
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Figure 1. Histograms specify number of individual compounds appearing in test set within regions
q2cv > 0.5 for traini g set against q2test L–7–O CV for modeling: AChE (a); nd BChE (b) potency of
proline-based carbamates derivatives with CoMSA method.
As an additional experiment, the PCA procedure for an ensemble of descriptors retrieved from
Dragon 6.0 software (Nuance Communications, Burlington, MA, USA) has been applied to the
analyzed compounds. The final dataset was arranged in matrix X25×2821 with rows representing
molecules (called objects) and columns presenting numerical parameters (called variables) for further
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analysis. PCA was applied to visualize major differences in the performance of investigated molecules
with respect to their structure and inhibitory profile. The analysis was performed for centered and
standardized data. The PCA model with first four PCs described 71.88% of the total data variance,
while the first three PCs account for 64.68%. The respective score plots are presented in Figure 2a,b.
An analysis of score plots PC1 vs. PC2 in Figure 2a and PC1 vs. PC3 in Figure 2b indicates that,
basically, proline-based carbamate derivatives can be classified into groups considering structural
data—the positional isomers are generally grouped together. PC1, which describes 43.03% of total
variance, reveals the major variations between compounds 1 and 7a–c (used as template molecules
in CoMSA analysis) and all the remaining ones. Indeed, molecule 1 (object no. 1) is unmodified
(only hydrogen substituent) compared to its derivatives containing CF3 group (compounds 7a–c)
characterized by the highest value of the volume descriptors provided by the Sybyl–X 2.0 software.
Not surprisingly, the visualization of objects encoded by a set of Dragon descriptors (parameters) on
the plane defined by PC1 vs. PC2 indicates a similar relationship within the ensemble of carbamate
analogs along the first principal component, especially for molecules 4–6c excluded from the best
models. Interestingly, this group of compounds is characterized by large negative values on PC2 as
illustrated in Figure 2a.
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third (b) principal components for Dragon descriptors.
Similarly, 15 parameters (variables) produced by the Sybyl software were collected including
count, volume, surface, Ro5 and lipophilicity descriptors (see Table 1 and Table S1 in Supplementary
materials) to examine the variations within the ensemble of carbamate derivatives. The compression
of the data slowly increased with the number of PCs that were included. The first two PCs account for
70.30% of the total data variance, and it increases to ca. 81.47% for next four PCs. The score and the
corresponding loading plots are presented in Figure 3a,b. The projection of objects on the plane defined
by PC1 vs. PC2 component confirmed the observed previously tendency to cluster compounds 4–6c
together with noticeable dissimilarities to positional isomers 8 (containing NO2 substituent). On the
basis of the loading plots (Figure 3b), it could be concluded that the uniqueness of the above molecules
was caused by the positively correlated variables describing the molecular prosperities (e.g., clogP, MW
or polar volume along PC1). Moreover, compounds 5–7 were also clustered more or less according to
Lipinski rule of five (Ro5) violations (isomers meta/para) as displayed in Figure 4a.
Basically, one can expect that the lipophilic profile for molecules can be related to their chemical
structure, therefore structurally similar compounds, namely chemotypes, should have similar property
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features. The detailed inspection of compound lipophilicity color-coded accordingly to calculated
values of clogP for objects projected on the plane specified by two first principal components (PC1 vs.
PC2) confirmed this tendency as observed in Figure 4b for compound separation detected along PC1
(compounds 5–7 with clogP > 5).
Molecules 2017, 22, 1969 7 of 25 
 
calculated values of clogP for objects projected on the plane specified by two first principal components 
(PC1 vs. PC2) confirmed this tendency as observed in Figure 4b for compound separation detected 
along PC1 (compounds 5–7 with clogP > 5). 
Figure 3. Projection of carbamates 1–9c on plane specified by first vs. second principal component (a); 
and corresponding loadings score for Sybyl descriptors (b). 
Figure 4. Projection of carbamates 1–9c on plane defined by first vs. second principal component with: 
number of Ro5 rule violations (a); and molecule lipophilicity profile (b). Colors code the number of Ro5 
violations and value of calculated lipophilicity. 
2.3. Consensus-Based 3D Pharmacophore Mapping 
Thousands of highly correlated topologic/topographic-based descriptors are normally generated 
in mD-QSAR studies; however, the informative variable selection is not an indispensable 
pre-processing procedure to prune the input assemble of generated descriptors. 
The subsequent level of variable elimination was applied in order to generate meaningful and 
predictive models. The recursive IVE-PLS procedure was employed as a “sieve” to identify 
structural descriptors having the highest individual weightings to the biological activity [50]. Hence, 
all 18/7 training/test samplings specified for regions with pretty high model abilities ( 2cvq  ≥ 0.5) were 
selected to produce an “average” pharmacophore. Regarding the number of objects, the maximum 
number of PLS components considered for the model generation was truncated to 7. Thus, the 
Figure 3. Projection of carba ates 1–9c on plane specified by first vs. second principal co ponent (a);
and corresponding loadings score for Sybyl descriptors (b).
Molecules 2017, 22, 1969 7 of 25 
 
calculated values of clogP for objects projected on the plane specified by two first principal components 
(PC1 vs. PC2) confirmed this tendency as observed in Figure 4b for compound separation detected 
along PC1 (compounds 5–7 with clogP > 5). 
Figure 3. Projection of carbamates 1–9c on plane specified by first vs. second principal component (a); 
and corresponding loadings score for Sybyl descriptors (b). 
Figure 4. Projection of carbamates 1–9c on plane defined by first vs. second principal component with: 
number of Ro5 rule violations (a); and molecule lipophilicity profile (b). Colors code the number of Ro5 
violations and value of calculated lipophilicity. 
2.3. Consensus-Based 3D Pharmacophore Mapping 
Thousands of highly correlated topologic/topographic-based descriptors are normally generated 
in mD-QSAR studies; however, the informative variable selection is not an indispensable 
pre-processing procedure to prune the input assemble of generated descriptors. 
The subsequent level of variable elimination was applied in order to generate meaningful and 
predictive models. The recursive IVE-PLS procedure was employed as a “sieve” to identify 
structural descriptors having the highest individual weightings to the biological activity [50]. Hence, 
all 18/7 training/test samplings specified for regions with pretty high model abilities ( 2cvq  ≥ 0.5) were 
selected to produce an “average” pharmacophore. Regarding the number of objects, the maximum 
number of PLS omponents considered for t e model genera ion was truncated to 7. Thus, the 
. j ti t l fi fi t . i i l t it :
f o5 rule violations (a); and molecule li ophilicity profile (b). Colors cod the number f
Ro5 v latio s and value of calculated lipophilicity.
2.3. Consensus-Based 3D Pharmacophore Mapping
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The subsequent level of variable elimination was applied in order to generate meaningful and
predictive models. The recursiv IVE-PLS proce re as employed as a “sieve” to identify structural
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descriptors having the highest individual weightings to the biological activity [50]. Hence, all 18/7
training/test samplings specified for regions with pretty high model abilities (q2cv ≥ 0.5) were selected
to produce an “average” pharmacophore. Regarding the number of objects, the maximum number of
PLS components considered for the model generation was truncated to 7. Thus, the columns annotated
with the highest stability for each of the randomly chosen models were identified using the IVE-PLS
methodology. Basically, a minor improvement of the q2cv performance was observed, while columns
from the data matrix assigned with the lowest value of abs(mean(b)/std(b)) were extracted; however,
the model predictability monitored by q2test remains stable for a considerable range of variables
eliminated in the majority of training/test samplings. The moment of q2cv deterioration determines
the number of the relevant columns, hence the backward column elimination is recurrently repeated
until the optimal number of variables included within the model is accomplished. The cumulative
sum of common columns for all investigated AChE or BChE models was calculated and normalized to
the range of (0–1). Initially, the group of columns with the value above the pre-chosen cut-off of 0.4
was selected, but the spatial pattern illustrated in Figure 5 was generated by further filtering of 50% of
CoMSA descriptors with relatively small statistical significance for the inhibitory activities. The relative
contribution of each variable is weighted by the magnitude and the sign of the corresponding regression
coefficient; therefore colors code the sign of the descriptor impact on compound potency. A visual
inspection of the key pharmacophore patterns can provide direct knowledge about the interaction mode
that increases/decreases the compound activity. The sign of influence is color-coded depicting not
only regions with positive and/or negative activity contribution, but also four possible combinations
of the mean charge/correlation coefficient.
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The dark spheres in Figure 5a indicate the patterns potentially detrimental for the BChE
inhibitory potency (mainly due to steric hindrance or electrostatic factors), while the bright polyhedral
specify the 3D areas where atom/substituent is predicted to be positioned in order to enhance the
compound’s inhibition profile. In fact, large regions with suggested favorable contribution appear
in the close proximity to the nitrogen attached directly to the carbonyl moiety (peptide-bond-like
motif in the scaffold). It suggests that the positively charged hydrogen bonded to this nitrogen atom
can be significant for the affinity of the inhibitor molecule, while interacting non-covalently with
a macromolecular site (hydrogen bond donor) as indicated by the corresponding positive regression
coefficient pool in Figure 5b. Moreover, the obtained findings demonstrate the importance of the side
chain R directly attached to the phenyl ring (see Table 1); especially positions 3′ and/or 4′ seem to be
a crucial structural and physicochemical factor for the activity maintenance of the tested compounds.
As a matter of fact, the mixed (negative/positive) steric contribution to the inhibitory efficiency is
observed in Figure 5a; however, the increase of bulkiness at position 4′ of the phenyl ring seem to be
unfavorable structural variations, which can partially explain the lower BChE potency of para isomers.
In general, the negatively charged atoms/groups in para position primarily favorably contribute
(negative regression coefficients) to the inhibition efficiency as illustrated in Figure 5b. On the other
hand, the spatially allowed areas attributed by the positive regression coefficient of CoMSA models
are occupied by the positively-charged carbon atom of CF3 or nitrogen of NO2 fragments, which
corresponds quite well with the enhanced inhibitory activities (AChE & BChE < 100) observed for CF3
and NO2 substituted derivatives within the ortho population.
The stochastic SMV protocol for the pharmacophore visualization based on the consensus 3D
QSAR modeling with satisfactory statistical characteristics provides the spatial map of chemical
groups/atoms potentially relevant for increasing/decreasing the activity profile of the proline-based
carbamates as potential ChEIs.
2.4. Molecular Docking Study
In the target-guided QSAR procedures the complementary (bio)effector binding mode is
retrieved based on the intrinsic dependence of atomic coordinates of both receptor and ligand in
the binding/active site, while the target spatial arrangement of atoms is available [51]. The adopted
spatial distribution of the ligand property space is mediated by the corresponding mapping of target
steric, electronic or lipophilic patterns. The promising site-directed QSAR methodology called docking
can be employed when the macromolecular geometry or at least good homology models are available.
Molecular docking is a method extensively used in the structure based drug design (SBDD); however;
this method does not always provide quantitative correlations between in silico calculations and actual
activity assays [52]. On the other hand, the SBDD methodology is a sophisticated tool in the lead
optimization and virtual screening of the hits retrieved from the ligand database in flash docking.
In particular, the structures of human acetylcholinesterase in a complex with pharmacologically
relevant drugs (e.g., galanthamine or rivastigmine) were a matter of previous extensive studies [53]
that allowed us to make a comparison with ligand-based protocols; however, the detailed investigation
of host–target interactions is beyond the scope of this paper.
The crystallographic data of rhAChE with the catalytic core specified at higher resolution of 2.4 Å
in the liganded state (holo) with galanthamine was obtained from 4EY6 PDB entry. Subsequently, the
drug molecule was successfully (re)docked into the active site of the enzyme chain A using AutoDock
Vina program (Scripps Research Institute, La Jolla, CA, USA) [54], which represents a flexible platform
for the rapid database screening as presented in Figure 6.
Moreover, the attempt to investigate the spatial host–rhAChE patterns within the active site
of chain A was taken for the population of proline-based carbamates (1–9c) and compared with
galanthamine interacting mode. Firstly, the comparison of particular conformations and mutual
orientations (poses) for compounds 1 and 7a–c is illustrated in Figure 7, indicating relevant structural
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variations in the catalytic binding site. It seems that para-substituted derivatives exert potentially
different impact on the enzyme reaction site, which is in line with our receptor-independent findings.Molecules 2017, 22, 1969 10 of 25 
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position of the phenyl ring is unfavorable for the inhibitory potency of the investigated carbamates as
observed also in the pharmacophore study.
Ironically, most ligand based results do not seem to be consistent with the structure based findings;
therefore we should beware of docking [55]. On the other hand, a systematic screening of multifaceted
drug-receptor bonding/repulsive forces using target-tailored procedures conjugated with consensus
pharmacophore mapping can lead towards an intelligent drug delivery platform.Molecules 2017, 22, 1969 11 of 25 
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2.5. I itro ytotoxicity ssay
reli i i vitro scre ning of the cytotoxicity of the ost ef ective co poun s as
perfor e t e human monocytic leukemia THP-1 cell line, as described previously [8].
The cytotoxicity was evaluated as the IC50 value (compou d concentration causing 50% inhibition
of cel p pulation pr liferation) (see Table 1). A compound is considered as cytotoxic when it
demonstrates a toxic effect cells at the concentration up to 10 µM [56], and the highest tested
concentrati n at was used for the toxicity assay was thr e times this value. Treatment with 30 µM
of the discusse c mpounds did not lead to a significant lethal effect on THP-1 cells. Based on these
observations, it c n be concl de that the discussed compounds can be considered as non-toxic agents
for subsequent design of novel drugs.
3. t ri l t s
3.1. General Methods
All reagents were purchased from Aldrich. TLC experiments were performed on alumina-backed
silica gel 60 F254 plates (Merck, Darmstadt, Germany). The plates were illuminated under UV
(254 nm). The melting points were determined on Böetius PHMK 05 (Franz Küstner Nachf, Dresden,
Germany) and are uncorrected. The purity of final compounds was analyzed by a Dionex Ultimate 3000
(Thermo Scientific) HPLC system controlled through the Chromeleon® Chromatography Data System
(version 7.2, Thermo Scientific, Waltham, MA USA). The separation was performed on a YMC-Tiart C18
(3 µm, 150 mm × 2 mm) column (Agilent Technologies, Waldbronn, Germany). Mobile phase consists
of water and acetonitrile in the ratio of 40:60. The total flow rate was 0.2 mL/min; the injection volume
was 1 µL; and the column temperature was maintained at 35 ◦C. The detection wavelength of 210 nm
was chosen. The purity of individual compounds was calculated as the average of relative peak areas
in the chromatograms of the sample solution. The measurement of optical rotations was carried on
Automatic polarimeter AA-10 (Optical Activity, Ramsey, UK). The concentration of samples is given in
g/100 mL. Infrared (IR) spectra were recorded on a Smart MIRacleTM ATR ZnSe for NicoletTM Impact
410 FT-IR Spectrometer (Thermo Scientific). The spectra were obtained by accumulation of 256 scans
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with 2 cm−1 resolution in the region of 4000–600 cm−1. All 1H, 19F and 13C spectra were recorded on
a JEOL ECZR 400 MHz NMR spectrometer (400 MHz for 1H, 101 MHz for 13C and 376 MHz for 19F,
Jeol, Tokyo, Japan) in DMSO-d6. Chemical shifts (δ) are reported in ppm. In 1H-NMR spectra there
are very broad signals due to interconversion of carbamate rotamers. In 13C and 19F NMR spectra
two signals for two rotamers are observed in most cases [57]. High-resolution mass spectra were
measured using a high-performance liquid chromatograph Dionex UltiMate® 3000 (Thermo Scientific)
coupled with a LTQ Orbitrap XLTMHybrid Ion Trap-Orbitrap Fourier Transform Mass Spectrometer
(Thermo Scientific) with injection into HESI II in the positive or negative mode.
3.2. Synthesis
General Procedure for Synthesis of Carbamates 1–8c: To a mixture of an appropriate aniline
(3.01 mmol, 1.5 equivalent) and N-benzyloxycarbonyl-L-proline (2.06 mmol) in dry ethyl acetate (5 mL)
propylphosphonic anhydride (T3P, 50% solution in toluene, 4.01 mmol of T3P, 2 equivalent) was
added dropwise. The reaction mixture was stirred overnight at 80 ◦C under atmosphere of argon.
Reaction was monitored by thin layer chromatography. After disappearance of the starting material,
water (10 mL) and ethyl acetate (10 mL) were added. The pH of the reaction mixture was adjusted to
pH 6 using 5 M NaOH solution. Organic layer was separated, washed twice with water and dried with
anhydrous Na2SO4, and solvent was evaporated under reduced pressure. The residue was triturated
with diethyl ether/petroleum ether or purified by column chromatography on silica gel (hexane/ethyl
acetate; v/v, 2:1) to give 1–8c. All the studied compounds are presented in Table 1.
Benzyl (2S)-2-(phenylcarbamoyl)pyrrolidine-1-carboxylate (1) [45]. Yield 80%; m.p. 140–141 ◦C; HPLC
pur. 99.39%; [α]25D : −123.3 (c 1.0, CHCl3) 1H-NMR (DMSO-d6) δ: 10.03 (d, J = 4.4 Hz, 1H),
7.59 (dd, J = 7.2, 5.6 Hz, 2H), 6.97–7.45 (m, 8H), 4.88–5.17 (m, 2H), 4.25–4.47 (m, 1H), 3.21–3.63
(m, 2H), 2.09–2.38 (m, 1H), 1.75–2.06 (m, 3H); 13C-NMR (DMSO-d6) δ: 170.99, 170.70, 153.69, 139.00,
138.92, 136.95, 136.77, 128.64, 128.62, 128.04, 127.47, 126.86, 123.28, 123.20, 119.32, 119.15, 65.91, 65.84,
60.47, 59.95, 47.22, 46.57, 31.28, 30.20, 23.96, 23.16; IR (cm−1): 3270, 2874, 1698, 1666, 1549, 1425, 1355,
1245, 1179, 1124, 986, 905, 758, 698; HR-MS: for C19H20N2O3 [M + H]+ calculated 325.1547 m/z, found
325.1548 m/z.
Benzyl (2S)-2-[(2-methoxyphenyl)carbamoyl]pyrrolidine-1-carboxylate (2a) [57]. Yield 67%; m.p. 74–76 ◦C;
HPLC pur. 99.57%; [α]25D : −107.0 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 9.20 (s, 1H), 7.90–8.05 (m, 1H),
6.99–7.45 (m, 7H), 6.85–6.96 (m, 1H), 4.92–5.17 (m, 2H), 4.57 (t, J = 9.3 Hz, 1H), 3.69–3.89 (m, 3H),
3.23–3.58 (m, 2H), 2.04–2.32 (m, 1H), 1.76–2.03 (m, 3H); 13C-NMR (DMSO-d6) δ: 171.04, 170.58, 153.80,
149.51, 136.84, 128.37, 128.05, 127.42, 126.88, 124.38, 121.68, 121.68, 121.08, 120.21, 119.43, 111.09, 65.98,
65.84, 60.40, 59.82, 55.70, 47.22, 46.63, 31.35, 29.85, 23.96, 23.11; IR (cm−1): 3274, 2963, 1705, 1684, 1536,
1414, 1351, 1251, 1120, 1025, 955, 745, 698; HR-MS: for C20H22N2O4 [M + H]+ calculated 355.1652 m/z,
found 355.1654 m/z.
Benzyl (2S)-2-[(3-methoxyphenyl)carbamoyl]pyrrolidine-1-carboxylate (2b). Yield 79%; m.p. 118–120 ◦C;
HPLC pur. 98.89%; [α]25D : −115.6 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 10.03 (d, J = 3.7 Hz, 1H),
7.29–7.41 (m, 3H), 7.08–7.26 (m, 5H), 6.60–6.68 (m, 1H), 4.92–5.13 (m, 2H), 4.30–4.40 (m, 1H), 3.70–3.75
(m, 3H), 3.30–3.56 (m, 2H), 2.11–2.33 (m, 1H), 1.78–1.99 (m, 3H); 13C-NMR (DMSO-d6) δ: 171.07, 170.79,
159.48, 154.02, 153.68, 140.21, 140.12, 136.95, 136.79, 129.45, 129.43, 128.38, 128.04, 127.49, 126.86, 111.57,
111.39, 108.89, 108.82, 104.99, 104.80, 65.93, 65.85, 60.50, 60.00, 54.97, 54.95, 47.22, 46.58, 31.27, 30.20,
23.96, 23.15; IR (cm−1): 3262, 2944, 1697, 1671, 1597, 1550, 1425, 1349, 1200, 1121, 1049, 955, 879, 768,
700; HR-MS: for C20H22N2O4 [M + H]+ calculated 355.1652 m/z, found 355.1653 m/z.
Benzyl (2S)-2-[(4-methoxyphenyl)carbamoyl]pyrrolidine-1-carboxylate (2c) [45,58]. Yield 58%; m.p.
122–124 ◦C; HPLC pur. 98.84%; [α]25D : −126.0 (c 1.0, CHCl3) 1H-NMR (DMSO-d6) δ: 9.88 (d, J = 4.8 Hz,
1H), 7.44–7.58 (m, 2H), 7.10–7.42 (m, 5H), 6.82–6.95 (m, 2H), 4.91–5.12 (m, 2H), 4.26–4.38 (m, 1H),
3.72 (d, J = 2.4 Hz, 3H), 3.27–3.57 (m, 2H), 2.08–2.32 (m, 1H), 1.71–2.00 (m, 3H); 13C-NMR (DMSO-d6)
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δ: 170.50, 170.20, 155.25, 155.16, 154.02, 153.71, 136.96, 136.81, 132.17, 132.04, 128.37, 128.08, 127.46,
126.86, 120.91, 120.68, 113.75, 65.89, 65.82, 60.41, 59.90, 55.15, 47.22, 46.58, 31.31, 30.23, 23.97, 23.17;
IR (cm−1): 3274, 2940, 1696, 1668, 1550, 1509, 1444, 1411, 1358, 1244, 1167, 1119, 1035, 836, 766, 697;
HR-MS: for C20H22N2O4 [M + H]+ calculated 355.1652 m/z, found 355.1655 m/z.
Benzyl (2S)-2-[(2-methylphenyl)carbamoyl]pyrrolidine-1-carboxylate (3a) [58]. Yield 73%; m.p. 115–117 ◦C;
HPLC pur. 98.99%; [α]25D : −123.0 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 9.39 (br. s., 1H), 7.03–7.46
(m, 10H), 5.00–5.15 (m, 2H), 4.43 (t, J = 9.4 Hz, 1H), 3.27–3.61 (m, 2H), 2.04–2.35 (m, 3H + 1H), 1.77–2.03
(m, 3H); 13C-NMR (DMSO-d6) δ: 170.93, 170.60, 154.19, 153.82, 136.98, 136.84, 136.03, 135.90, 132.29,
130.19, 128.36, 128.21, 127.20, 125.83, 125.45, 65.94, 60.31, 59.67, 47.18, 46.58, 31.46, 30.16, 24.01, 23.17,
17.69, 17.59; IR (cm−1): 3258, 2948, 1715, 1662, 1528, 1416, 1353, 1130, 995, 737, 697; HR-MS: for
C20H22N2O3 [M + H]+ calculated 339.1703 m/z, found 339.1706 m/z.
Benzyl (2S)-2-[(3-methylphenyl)carbamoyl]pyrrolidine-1-carboxylate (3b) [58]. Yield 65%; m.p. 101–103 ◦C;
HPLC pur. 99.68%; [α]25D : −122.5 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 9.96 (d, J = 6.9 Hz, 1H),
7.29–7.49 (m, 4H), 7.07–7.28 (m, 4H), 6.81–6.93 (m, 1H), 4.90–5.14 (m, 2H), 4.35 (ddd, J = 15.7, 8.3, 3.0 Hz,
1H), 3.31–3.56 (m, 2H), 2.13–2.32 (m, 3H + 1H), 1.77–1.98 (m, 3H); 13C-NMR (DMSO-d6) δ: 171.02,
170.73, 154.08, 153.76, 138.97, 138.86, 137.91, 137.85, 137.01, 136.85, 128.46, 128.12, 127.54, 126.94, 124.05,
123.96, 120.00, 119.77, 116.61, 116.40, 65.99, 65.89, 60.52, 60.01, 47.27, 46.63, 31.34, 30.26, 24.01, 23.20,
21.22; IR (cm−1): 3274, 2874, 1670, 1557, 1425, 1351, 1203, 1125, 951, 749, 696; HR-MS: for C20H22N2O3
[M + H]+ calculated 339.1703 m/z, found 339.1706 m/z.
Benzyl (2S)-2-[(4-methylphenyl)carbamoyl]pyrrolidine-1-carboxylate (3c) [58]. Yield 76%; m.p. 143–146 ◦C;
HPLC pur. 99.81%; [α]25D : −122.0 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 9.94 (d, J = 5.5 Hz, 1H),
7.42–7.52 (m, 2H), 7.28–7.41 (m, 2H), 7.07–7.26 (m, 5H), 4.92–5.13 (m, 2H), 4.35 (ddd, J = 11.4, 8.2, 3.1 Hz,
1H), 3.35–3.57 (m, 2H), 2.21–2.29 (m, 3H + 1H), 1.79–2.01 (m, 3H); 13C-NMR (DMSO-d6) δ: 170.76,
170.46, 154.01, 153.70, 136.96, 136.80, 136.40, 132.18, 129.01, 128.98, 128.37, 128.06, 127.46, 126.85, 119.40,
119.17, 65.90, 65.83, 60.44, 59.92, 47.22, 46.57, 31.30, 30.22, 23.96, 23.15, 20.43; IR (cm−1): 3270, 2874, 1695,
1668, 1514, 1428, 1352, 1251, 1123, 955, 819, 749, 697; HR-MS: for C20H22N2O3 [M + H]+ calculated
339.1703 m/z, found 339.1705 m/z.
Benzyl (2S)-2-[(2-fluorophenyl)carbamoyl]pyrrolidine-1-carboxylate (4a) [45]. Yield 96%; m.p. 113–115 ◦C;
HPLC pur. 98.66%; [α]25D : −110.6 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 9.85 (s, 1H), 7.76–7.92 (m, 1H),
7.35–7.40 (m, 2H), 7.29–7.34 (m, 1H), 7.18–7.29 (m, 3H), 7.11–7.18 (m, 2H), 4.96–5.13 (m, 2H), 4.49–4.57
(m, 1H), 3.40–3.56 (m, 2H), 2.15–2.32 (m, 1H), 1.80–1.98 (m, 3H); 13C-NMR (DMSO-d6) δ: 171.50, 171.13,
154.10, 153.76 (d, 1JCF = 244.2 Hz, 1C), 153.68, 153.54 (d, 1JCF = 244.2 Hz, 1C), 136.97, 136.79, 128.37,
128.08, 127.75, 127.48, 127.44, 126.94, 125.97 (d, 2JCF = 22.0 Hz, 1C), 125.89 (d, 2JCF = 21.7 Hz, 1C), 125.39
(d, 3JCF = 7.5 Hz, 1C), 125.38 (d, 3JCF = 7.2 Hz, 1C), 125.23 (d, 3JCF = 7.5 Hz, 1C), 125.22 (d, 3JCF = 7.2 Hz,
1C), 124.29 (d, 2JCF = 21.7 Hz, 1C), 124.21 (d, 4JCF = 3.5 Hz, 2C), 124.15 (d, 2JCF = 22.0 Hz, 1C),
115.48, 115.35, 65.94, 65.87, 60.10, 59.54, 47.18, 46.58, 31.34, 30.14, 23.93, 23.11; 19F NMR (DMSO-d6)
δ: −124.91–−124.76 (m, 1F), −124.75–−124.53 (m, 1F); IR (cm−1): 3266, 2878, 1672, 1537, 1421, 1353,
1254, 1122, 986, 762, 744, 696; HR-MS: for C19H19FN2O3 [M − H]− calculated 341.1307 m/z, found
341.1309 m/z.
Benzyl (2S)-2-[(3-fluorophenyl)carbamoyl]pyrrolidine-1-carboxylate (4b). Yield 96%; m.p. 82–84 ◦C; HPLC
pur. 98.93%; [α]25D : −109.3 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 10.26 (s, 1H), 7.59 (t, J = 11.2 Hz,
1H), 7.26–7.43 (m, 4H), 7.06–7.25 (m, 3H), 6.83–6.94 (m, 1H), 4.89–5.15 (m, 2H), 4.29–4.41 (m, 1H),
3.26–3.58 (m, 2H), 2.12–2.35 (m, 1H), 1.76–2.03 (m, 3H); 13C-NMR (DMSO-d6) δ: 171.40, 171.12, 162.10
(d, 1JCF = 241.2 Hz, 1C), 162.09 (d, 1JCF = 241.4 Hz, 1C), 154.04, 153.65, 140.73 (d, 3JCF = 6.9 Hz, 1C),
140.59 (d, 3JCF = 6.6 Hz, 1C), 136.92, 136.73, 130.33 (d, 3JCF = 9.7 Hz, 1C), 130.28 (d, 3JCF = 9.4 Hz, 1C),
128.38, 128.01, 127.79, 127.48, 127.46, 126.94, 115.05 (d, 4JCF = 2.5 Hz, 1C), 114.80 (d, 4JCF = 2.7 Hz,
1C), 109.76 (d, 2JCF = 21.3 Hz, 1C), 109.69 (d, 2JCF = 21.3 Hz, 1C), 106.12 (d, 2JCF = 26.2 Hz, 1C),
105.95 (d, 2JCF = 26.5 Hz, 1C), 65.97, 65.91, 60.52, 60.01, 47.22, 46.58, 31.21, 30.15, 23.98, 23.17; 19F NMR
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(DMSO-d6) δ: −112.13–−112.00 (m, 1 F), −111.99–−111.88 (m, 1F); IR (cm−1): 3503, 3021, 1671, 1607,
1432, 1356, 1297, 1205, 1122, 961, 874, 769, 699; HR-MS: for C19H19FN2O3 [M − H]− calculated
341.1307 m/z, found 341.1309 m/z.
Benzyl (2S)-2-[(4-fluorophenyl)carbamoyl]pyrrolidine-1-carboxylate (4c) [45]. Yield 96%; m.p. 122–124 ◦C;
HPLC pur. 99.53%; [α]25D : −116.8 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 10.09 (s, 1H), 7.60
(td, J = 9.6, 5.0 Hz, 2H), 7.08–7.41 (m, 7H), 4.90–5.14 (m, 2H), 4.27–4.39 (m, 1H), 3.37–3.57 (m, 2H),
2.11–2.33 (m, 1H), 1.78–2.01 (m, 3H); 13C-NMR (DMSO-d6) δ: 170.92, 170.63, 158.01 (d, 1JCF = 239.8 Hz,
1C), 157.95 (d, 1JCF = 240.1 Hz, 1C), 154.03, 153.69, 136.94, 136.75, 135.39 (d, 4JCF = 2.5 Hz, 1C), 135.29
(d, 4JCF = 2.5 Hz, 1C), 128.37, 128.05, 127.77, 127.47, 126.90, 121.09 (d, 3JCF = 7.5 Hz, 2C), 120.91
(d, 3JCF = 7.7 Hz, 2C), 115.22 (d, 2JCF = 22.1 Hz, 2C), 115.19 (d, 2JCF = 22.1 Hz, 2C), 65.94, 65.87,
60.46, 59.94, 47.22, 46.58, 31.25, 30.19, 23.98, 23.17; 19F NMR (DMSO-d6) δ: −119.35–−119.25 (m, 1F),
−119.23–−119.13 (m, 1F); IR (cm−1): 3278, 3080, 1668, 1555, 1426, 1354, 1214, 1196, 1128, 959, 741, 696;
HR-MS: for C19H19FN2O3 [M − H]− calculated 341.1307 m/z, found 341.1309 m/z.
Benzyl (2S)-2-[(2-chlorophenyl)carbamoyl]pyrrolidine-1-carboxylate (5a). Yield 85%; m.p. 76–78 ◦C; HPLC
pur. 98.84%; [α]25D : −106.0 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 9.55–9.64 (m, 1H), 7.71 (d, J = 7.6 Hz,
1H), 7.48 (t, J = 6.5 Hz, 2H), 7.24–7.41 (m, 5H), 7.20 (t, J = 7.3 Hz, 1H), 4.99–5.13 (m, 2H), 4.47–4.55
(m, 1H), 3.48–3.56 (m, 1H), 3.44 (t, J = 7.3 Hz, 1H), 2.16–2.33 (m, 1H), 1.96–2.03 (m, 1H), 1.81–1.96
(m, 2H); 13C-NMR (DMSO-d6) δ: 171.27, 170.89, 154.30, 153.79, 136.92, 136.81, 134.66, 134.55, 129.41,
128.19, 127.46, 127.13, 126.56, 125.85, 66.02, 65.94, 60.35, 59.70, 47.18, 46.60, 31.31, 29.97, 23.96, 23.11;
IR (cm−1): 3266, 1677, 1524, 1423, 1354, 1291, 1181, 1121, 1041, 955, 761, 698; HR-MS: for C19H19ClN2O3
[M − H]− calculated 357.1011 m/z, found 357.1017 m/z.
Benzyl (2S)-2-[(3-chlorophenyl)carbamoyl]pyrrolidine-1-carboxylate (5b). Yield 79%; m.p. 101–103 ◦C;
HPLC pur. 99.08%; [α]25D : −117.8 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 10.23 (br. s., 1H), 7.76–7.85
(m, 1H), 7.44 (dd, J = 18.2, 8.2 Hz, 1H), 7.28–7.39 (m, 3H), 7.16–7.26 (m, 2H), 7.06–7.15 (m, 2H), 5.03–5.14
(m, 1H), 4.93 (d, J = 12.9 Hz, 1H), 4.29–4.38 (m, 1H), 3.42–3.56 (m, 2H), 2.17–2.31 (m, 1H), 1.80–1.98
(m, 3H); 13C-NMR (DMSO-d6) δ: 171.43, 171.15, 154.06, 153.65, 140.39, 136.72, 132.99, 130.35, 128.39,
128.02, 127.48, 126.96, 123.04, 122.97, 118.91, 118.70, 117.73, 117.56, 65.98, 65.91, 60.55, 60.04, 47.22, 46.59,
31.19, 30.14, 23.98, 23.17; IR (cm−1): 3491, 3041, 1673, 1590, 1484, 1427, 1356, 1299, 1196, 1111, 882, 778,
743, 685; HR-MS: for C19H19ClN2O3 [M − H]− calculated 357.1011 m/z, found 357.1017 m/z.
Benzyl (2S)-2-[(4-chlorophenyl)carbamoyl]pyrrolidine-1-carboxylate (5c) [58]. Yield 76%; m.p. 121–123 ◦C;
HPLC pur. 98.79%; [α]25D : −113.6 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 10.17 (s, 1H), 7.56–7.68 (m, 2H),
7.27–7.44 (m, 5H), 7.08–7.26 (m, 2H), 5.04–5.14 (m, 1H), 4.90–4.98 (m, 1H), 4.29–4.40 (m, 1H), 3.42–3.57
(m, 2H), 2.12–2.34 (m, 1H), 1.79–1.99 (m, 3H); 13C-NMR (DMSO-d6) δ: 171.18, 170.89, 154.04, 153.67,
137.93, 137.84, 136.93, 136.73, 128.59, 128.55, 128.39, 128.07, 127.48, 126.91, 120.91, 120.74, 65.97, 65.90,
60.50, 60.00, 47.23, 46.59, 31.24, 30.17, 23.99, 23.18; IR (cm−1): 3270, 3184, 3064, 1704, 1673, 1542, 1445,
1359, 1300, 1167, 1117, 968, 840, 766, 732; HR-MS: for C19H19ClN2O3 [M−H]− calculated 357.1011 m/z,
found 357.1015 m/z.
Benzyl (2S)-2-[(2-bromophenyl)carbamoyl]pyrrolidine-1-carboxylate (6a) [59]. Yield 83%; m.p. 77–79 ◦C;
HPLC pur. 98.82%; [α]25D : −93.3 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 9.43–9.60 (m, 1H), 7.60–7.68
(m, 2H), 7.23–7.43 (m, 6H), 7.14 (t, J = 7.3 Hz, 1H), 5.00–5.15 (m, 2H), 4.43–4.54 (m, 1H), 3.39–3.58
(m, 2H), 2.16–2.34 (m, 1H), 2.03 (td, J = 11.3, 4.4 Hz, 1H), 1.81–1.98 (m, 2H); 13C-NMR (DMSO-d6)
δ: 171.07, 170.70, 154.30, 153.80, 136.90, 136.83, 135.86, 132.57, 128.36, 128.20, 127.21, 126.93, 126.49,
66.03, 65.96, 60.41, 59.76, 47.17, 46.58, 31.21, 29.91, 23.95, 23.09; IR (cm−1): 3239, 1717, 1670, 1522, 1414,
1353, 1201, 1125, 1029, 994, 728, 696; HR-MS: for C19H19BrN2O3 [M − H]− calculated 401.0506 m/z,
found 401.0513 m/z.
Benzyl (2S)-2-[(3-bromophenyl)carbamoyl]pyrrolidine-1-carboxylate (6b) [60]. Yield 75%; m.p. 124–126 ◦C;
HPLC pur. 98.69%; [α]25D : −92.0 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 10.21 (s, 1H), 7.92–7.99
(m, 1H), 7.49 (dd, J = 16.7, 7.9 Hz, 1H), 7.38 (d, J = 4.7 Hz, 2H), 7.16–7.34 (m, 4H), 7.09–7.16 (m, 1H),
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4.91–5.13 (m, 2H), 4.33 (ddd, J = 19.8, 8.4, 3.5 Hz, 1H), 3.40–3.55 (m, 2H), 2.17–2.30 (m, 1H), 1.80–1.98
(m, 3H); 13C-NMR (DMSO-d6) δ: 171.41, 171.12, 154.05, 153.64, 140.52, 140.40, 136.91, 136.72, 130.71,
130.64, 128.39, 128.02, 127.48, 126.96, 125.93, 125.87, 121.79, 121.50, 118.11, 117.94, 65.98, 65.91, 60.55,
60.04, 47.22, 46.58, 31.19, 30.14, 23.97, 23.17; IR (cm−1): 3254, 3173, 2878, 1701, 1668, 1591, 1418, 1352,
1258, 1128, 990, 874, 745, 667; HR-MS: for C19H19BrN2O3 [M − H]− calculated 401.0506 m/z, found
401.0513 m/z.
Benzyl (2S)-2-[(4-bromophenyl)carbamoyl]pyrrolidine-1-carboxylate (6c) [60]. Yield 93%; m.p. 109–111 ◦C;
HPLC pur. 99.10%; [α]25D : −100.0 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 10.17 (s, 1H), 7.43–7.63 (m, 4H),
7.27–7.42 (m, 2H), 7.08–7.26 (m, 3H), 4.90–5.12 (m, 2H), 4.29–4.39 (m, 1H), 3.35–3.58 (m, 2H), 2.13–2.31
(m, 1H), 1.76–1.99 (m, 3H); 13C-NMR (DMSO-d6) δ: 171.18, 170.90, 154.02, 153.64, 138.34, 138.24, 136.91,
136.71, 131.44, 128.37, 128.05, 127.46, 126.89, 121.28, 121.12, 65.95, 65.88, 60.51, 60.00, 47.20, 46.57, 31.21,
30.15, 23.97, 23.16; IR (cm−1): 3270, 1703, 1670, 1538, 1444, 1358, 1299, 1166, 1114, 1068, 1005, 967, 823,
731, 695; HR-MS: for C19H19BrN2O3 [M + H]+ calculated 403.0652 m/z, found 403.0658 m/z.
Benzyl (2S)-2-{[2-(trifluoromethyl)phenyl]carbamoyl}pyrrolidine-1-carboxylate (7a). Yield 65%; m.p.
82–84 ◦C; HPLC pur. 99.01%; [α]25D : −100.0 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 9.64 (d, J = 18.8 Hz,
1H), 7.56–7.76 (m, 2H), 7.26–7.52 (m, 6H), 7.14 (d, J = 7.6 Hz, 1H), 5.01–5.17 (m, 2H), 4.41–4.53
(m, 1H), 3.35–3.57 (m, 2H), 2.14–2.32 (m, 1H), 1.80–1.99 (m, 3H); 13C-NMR (DMSO-d6) δ: 171.86,
171.55, 153.81, 136.91, 135.25, 135.13 (q, 4JCF = 1.1 Hz, 2C), 132.99, 132.86, 129.97, 129.69 (q, 4JCF = 0.9 Hz,
2C), 128.37, 128.27, 127.77, 127.69, 127.46, 127.37, 126.82, 126.65, 126.26 (q, 3JCF = 5.2 Hz, 2C),
124.95 (q, 2JCF = 31.2 Hz, 1C), 124.94 (q, 2JCF = 30.3 Hz, 1C), 124.64 (q, 3JCF = 4.3 Hz, 2C), 123.56
(q, 1JCF = 273.7 Hz, 1C), 123.54 (q, 1JCF = 273.4 Hz, 1C), 122.65, 122.61, 66.01, 65.95, 60.17, 59.52, 47.15,
46.55, 30.99, 29.76, 23.85, 22.98; 19F NMR (DMSO-d6) δ: -59.24 (s, 1F), -59.31 (s, 1F); IR (cm−1): 3254,
1704, 1669, 1527, 1418, 1317, 1278, 1160, 1110, 1092, 909, 766, 691; HR-MS: for C20H19F3N2O3 [M − H]−
calculated 391.1275 m/z, found 391.1278 m/z.
Benzyl (2S)-2-{[3-(trifluoromethyl)phenyl]carbamoyl}pyrrolidine-1-carboxylate (7b). Yield 63%; m.p.
86–88 ◦C; HPLC pur. 99.54%; [α]25D : −100.0 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 10.38 (d, J = 4.8 Hz,
1H), 8.10 (d, J = 16.8 Hz, 1H), 7.72–7.85 (m, 1H), 7.49–7.62 (m, 1H), 7.27–7.46 (m, 3H), 6.99–7.24 (m, 3H),
4.85–5.18 (m, 2H), 4.36 (td, J = 8.7, 3.4 Hz, 1H), 3.36–3.59 (m, 2H), 2.14–2.37 (m, 1H), 1.76–2.05 (m, 3H);
13C-NMR (DMSO-d6) δ: 171.69, 171.41, 154.09, 153.67, 139.74, 139.64, 136.93, 136.73, 130.00, 129.95,
129.44 (q, 2JCF = 31.8 Hz, 1C), 129.41 (q, 2JCF = 31.8 Hz, 1C), 128.42, 127.97, 127.82, 127.53, 127.47, 126.99,
124.13 (q, 1JCF = 272.6 Hz, 2C), 122.86, 122.72, 119.67 (q, 4JCF = 1.0 Hz, 2C), 115.45 (q, 3JCF = 3.9 Hz,
2C), 115.25 (q, 3JCF = 3.9 Hz, 2C), 66.03, 65.95, 60.59, 60.10, 47.24, 46.61, 31.19, 30.15, 24.01, 23.20;
19F NMR (DMSO-d6) δ: −61.26 (s, 1F), −61.27 (s, 1F); IR (cm−1): 3270, 1694, 1674, 1545, 1419, 1325,
1165, 1123, 1111, 1063, 804, 740, 693; HR-MS: for C20H19F3N2O3 [M + H]+ calculated 393.1421 m/z,
found 393.1424 m/z.
Benzyl (2S)-2-{[4-(trifluoromethyl)phenyl]carbamoyl}pyrrolidine-1-carboxylate (7c) [61]. Yield 62%; m.p.
106–109 ◦C; HPLC pur. 99.68%; [α]25D : −98.8 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 10.37–10.47 (m, 1H),
7.75–7.86 (m, 2H), 7.68 (d, J = 8.2 Hz, 2H), 7.35–7.40 (m, 1H), 7.28–7.35 (m, 1H), 7.14–7.23 (m, 2H),
7.06–7.13 (m, 1H), 5.07 (s, 1H), 4.90–4.97 (m, 1H), 4.32–4.43 (m, 1H), 3.41–3.57 (m, 2H), 2.16–2.34
(m, 1H), 1.79–1.99 (m, 3H); 13C-NMR (DMSO-d6) δ: 171.73, 171.44, 154.10, 153.68, 142.58, 142.52, 136.95,
136.73, 128.41, 128.06, 127.82, 127.51 (q, 4JCF = 1.0 Hz, 4C), 126.98, 126.00 (q, 3JCF = 3.9 Hz, 4C), 124.42
(q, 1JCF = 271.7 Hz, 2C), 123.41 (q, 2JCF = 31.8 Hz, 1C), 123.34 (q, 2JCF = 31.8 Hz, 1C), 119.24, 119.11, 66.03,
65.98, 60.58, 60.09, 47.24, 46.61, 31.22, 30.17, 24.02, 23.20; 19F NMR (DMSO-d6) δ: -60.19 (s, 1F); IR (cm−1):
3301, 1719, 1672, 1527, 1408, 1324, 1273, 1156, 1110, 1067, 835, 767, 696; HR-MS: for C20H19F3N2O3
[M + H]+ calculated 393.1421 m/z, found 393.1424 m/z.
Benzyl (2S)-2-[(2-nitrophenyl)carbamoyl]pyrrolidine-1-carboxylate (8a). Yield 72%; oil; HPLC pur. 99.71%;
[α]25D : −92.3 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 10.46 (d, J = 14.1 Hz, 1H), 7.98 (d, J = 7.0 Hz,
1H), 7.56–7.85 (m, 2H), 7.11–7.45 (m, 6H), 4.93–5.18 (m, 2H), 4.31–4.49 (m, 1H), 3.37–3.63 (m, 2H),
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2.12–2.38 (m, 1H), 1.79–2.07 (m, 3H); 13C-NMR (DMSO-d6) δ: 171.03, 170.77, 164.51, 154.32, 153.76,
141.83, 136.80, 136.68, 134.29, 134.10, 131.15, 128.37, 128.15, 127.15, 125.01, 124.68, 119.43, 66.13, 66.02,
60.69, 60.13, 47.16, 46.59, 30.59, 29.49, 23.90, 23.08; IR (cm−1): 3320, 2955, 2870, 1694, 1606, 1582, 1496,
1398, 1336, 1266, 1072, 866, 742, 691; HR-MS: for C19H19N3O5 [M + H]+ calculated 370.1398 m/z, found
370.1401 m/z.
Benzyl (2S)-2-[(3-nitrophenyl)carbamoyl]pyrrolidine-1-carboxylate (8b). Yield 60%; m.p. 101–104 ◦C; HPLC
pur. 99.64%; [α]25D : −104.3 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 10.53 (d, J = 9.0 Hz, 1H), 8.52–8.77
(m, 1H), 7.93 (d, J = 6.6 Hz, 2H), 7.52–7.70 (m, 1H), 7.00–7.43 (m, 5H), 4.83–5.19 (m, 2H), 4.37 (dt, J = 8.2,
4.1 Hz, 1H), 3.39–3.63 (m, 2H), 2.12–2.40 (m, 1H), 1.74–2.04 (m, 3H); 13C-NMR (DMSO-d6) δ: 171.81,
171.53, 164.53, 153.63, 147.91, 147.87, 140.04, 139.93, 136.88, 136.65, 130.16, 130.11, 128.38, 127.99, 127.01,
125.30, 125.15, 117.87, 113.50, 113.34, 66.04, 65.97, 60.63, 60.15, 47.22, 46.55, 31.15, 30.11, 24.00, 23.20;
IR (cm−1): 3270, 3087, 2983, 1706, 1681, 1598, 1520, 1446, 1394, 1296, 1243, 1123, 893, 739, 664; HR-MS:
for C19H19N3O5 [M + H]+ calculated 370.1398 m/z, found 370.1400 m/z.
Benzyl (2S)-2-[(4-nitrophenyl)carbamoyl]pyrrolidine-1-carboxylate (8c) [62]. Yield 99%; m.p. 144–148 ◦C;
HPLC pur. 98.52%; [α]25D : −90.9 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 10.67 (d, J = 6.8 Hz, 1H),
8.08–8.36 (m, 2H), 7.70–7.99 (m, 2H), 7.02–7.48 (m, 5H), 4.84–5.19 (m, 2H), 4.28–4.52 (m, 1H), 3.38–3.60
(m, 2H), 2.16–2.39 (m, 1H), 1.75–2.04 (m, 3H); 13C-NMR (DMSO-d6) δ: 172.02, 171.71, 164.52, 154.06,
153.58, 145.11, 145.02, 142.29, 136.87, 136.61, 128.38, 128.06, 127.48, 126.96, 124.95, 124.89, 119.02, 118.92,
66.03, 66.00, 60.63, 60.12, 47.20, 46.57, 31.13, 30.08, 23.99, 23.17; IR (cm−1): 3344, 2854, 1705, 1662, 1553,
1507, 1421, 1337, 1252, 1111, 986, 852, 696; HR-MS: for C19H19N3O5 [M + H]+ calculated 370.1398 m/z,
found 370.1399 m/z.
General Procedure for Synthesis of Carbamates 9a–9c: N-benzyloxycarbonyl-L-proline (0.50 g,
2.06 mmol) and dry TEA (0.81 g, 8.0 mmol) were dissolved in dry THF (7.5 mL) and cooled to
0 ◦C. To this solution, ethyl chloroformate (0.22 g, 2.06 mmol) was added dropwise during 15 min.
The reaction mixture was then stirred for 30 min at the same temperature, and aminophenole (0.22 g,
2.06 mmol) was added. The resulting solution was stirred at 0 ◦C for 1 h and then at room temperature
under inert atmosphere overnight. After reaction was finished, water (10 mL) was added, and the
solution was three times extracted with diethyl ether. Combined organic layers were washed with
1M HCl, saturated NaHCO3 and brine and dried with anhydrous Na2SO4. Solvent was evaporated
under reduced pressure, and the residue was triturated with diethyl ether/petroleum ether to give
compounds 9a–9c. All the studied compounds are presented in Table 1.
Benzyl (2S)-2-[(2-hydroxyphenyl)carbamoyl]pyrrolidine-1-carboxylate (9a) [61]. Yield 98%; oil; HPLC pur.
98.51%; [α]25D : −101.3 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 9.81 (br. s., 1H), 9.25 (s, 1H), 7.83 (dd,
J = 13.8, 8.0 Hz, 1H), 7.12–7.43 (m, 6H), 6.70–6.99 (m, 2H), 4.95–5.21 (m, 2H), 4.45–4.65 (m, 1H), 3.38–3.57
(m, 2H), 2.06–2.39 (m, 1H), 1.77–2.04 (m, 3H); 13C-NMR (DMSO-d6) δ: 171.17, 170.74, 164.53, 153.87,
153.82, 147.53, 147.30, 136.84, 128.40, 128.11, 127.44, 126.84, 126.20, 124.45, 121.74, 118.92, 115.34, 115.25,
66.01, 65.86, 60.26, 59.89, 47.26, 46.66, 31.39, 30.02, 23.99, 23.14; IR (cm−1): 3658, 3282, 2944, 2870,
1767, 1663, 1597, 1526, 1452, 1414, 1348, 1165, 1103, 975, 746, 637; HR-MS: for C19H20N2O4 [M + H]+
calculated 341.1496 m/z, found 341.1500 m/z.
Benzyl (2S)-2-[(3-hydroxyphenyl)carbamoyl]pyrrolidine-1-carboxylate (9b) [63]. Yield 81%; m.p. 153–157 ◦C;
HPLC pur. 98.61%; [α]25D : −114.8 (c 1.0, CHCl3); 1H-NMR (DMSO-d6) δ: 9.90 (d, J = 17.9 Hz, 1H), 9.36
(d, J = 7.0 Hz, 1H), 7.29–7.42 (m, 3H), 6.93–7.25 (m, 5H), 6.41–6.51 (m, 1H), 4.93–5.13 (m, 2H), 4.21–4.41
(m, 1H), 3.38–3.56 (m, 2H), 2.24 (br. s., 1H), 1.77–1.98 (m, 3H); 13C-NMR (DMSO-d6) δ: 170.86, 170.55,
157.55, 154.00, 153.68, 139.96, 136.97, 136.79, 129.25, 128.38, 128.07, 127.46, 126.81, 110.39, 110.34, 110.08,
109.95, 106.52, 106.37, 65.90, 65.83, 60.46, 59.94, 47.22, 46.57, 31.30, 30.21, 23.95, 23.14; IR (cm−1): 3794,
3192, 2948, 2350, 1686, 1675, 1597, 1552, 1438, 1422, 1352, 1176, 1153, 1127, 1032, 1000, 973, 753, 687;
HR-MS: for C19H20N2O4 [M + H]+ calculated 341.1496 m/z, found 341.1502 m/z.
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Benzyl (2S)-2-[(4-hydroxyphenyl)carbamoyl]pyrrolidine-1-carboxylate (9c). Yield 60%; m.p. 193–194 ◦C;
HPLC pur. 98.52%; [α]25D : −70.7 (c 1.0, EtOH); 1H-NMR (DMSO-d6) δ: 9.76 (d, J = 14.1 Hz, 1H), 9.18
(d, J = 6.5 Hz, 1H), 7.28–7.43 (m, 4H), 7.12–7.27 (m, 3H), 6.65–6.73 (m, 2H), 4.93–5.13 (m, 2H), 4.25–4.36
(m, 1H), 3.39–3.55 (m, 2H), 2.12–2.28 (m, 1H), 1.77–1.97 (m, 3H); 13C-NMR (DMSO-d6) δ: 170.35, 170.10,
154.04, 153.77, 153.36, 137.01, 136.88, 130.69, 130.59, 128.40, 128.11, 127.48, 126.89, 121.21, 121.01, 115.01,
65.89, 60.45, 59.93, 47.25, 46.58, 31.35, 30.27, 23.99, 23.20; IR (cm−1): 3685, 3262, 2955, 1677, 1658,
1550, 1516, 1437, 1353, 1246, 1177, 1134, 995, 829, 691; HR-MS: for C19H20N2O4 [M + H]+ calculated
341.1496 m/z, found 341.1500 m/z.
3.3. In Vitro Evaluation of AChE- and BChE-Inhibiting Activity
The ability of all prepared compounds to inhibit AChE from electric eel (Electrophorus electricus)
and BChE from equine serum (both purchased from Sigma, St. Louis, MO, USA) was determined
in vitro using a modified Ellman’s method. The effectiveness of the inhibitors expressed as IC50
value represents the concentration of an inhibitor that is required for reduction of enzyme activity
(or reaction rate) to 50% (sometimes it is referred to as the negative logarithm of the molar concentration
inhibiting the enzyme activity by 50%, pIC50 = log 1/IC50). The Ellman’s method [64] is widely used for
measuring cholinesterase activity and the effectivity of ChEIs. It is a simple, rapid and direct method to
determine SH and –S–S– groups content in proteins [65]. Cholinesterase activity is measured indirectly
by quantifying the concentration of 5-thio-2-nitrobenzoic acid (TNB) ion formed in the reaction between
disulfide reagent 5,5′-dithiobis-2-nitrobenzoic acid (DTNB) and thiocholine, a product of substrate
(i.e., acetylthiocholine, ATCh) hydrolysis catalyzed by cholinesterase [66].
All tested compounds were dissolved in DMSO (concentration 0.01 M) and diluted in
demineralized water (concentrations 0.001 M and 0.0001 M). The ability of tested compounds to
inhibit AChE (from electric eel) and BChE (from equine serum) was determined using the modified
Ellman’s method at 25 ◦C in the presence of phosphate buffered saline (PBS, 0.1 M, pH 7.4) in a glass
cuvette with 1 cm optical path. The enzyme activity in total reaction mixture (2 mL) was 0.2 U/mL,
the concentration of substrate ATCh 40 µM and the concentration of DTNB 0.1 mM for all reactions.
The IC50 value was obtained from the dependence of v0/vi on the concentration of the tested compound
(inhibitor), where v0 is the reaction rate of uninhibited reaction and vi is the reaction rate of inhibited
reaction (for the given concentration of the inhibitor). First, v0 was determined. Into the cuvette
PBS (0.1 M, pH 7.4), DTNB and ATCh were placed. The enzymatic reaction was started by adding
the enzyme. The dependence of absorbance (λ = 412 nm) on time was observed for 70 s (reference
solution contained PBS, DTNB and ATCh), and then the reaction rate (v0) was calculated (v = ∆A/∆t).
The measurement was performed in triplicate at least, and average v0 was determined. Then, vi (for the
given concentration of the inhibitor) was determined. Into the cuvette DTNB, ATCh, a chosen volume
of the suitably diluted inhibitor (to achieve the required concentration of the inhibitor in the total
reaction mixture) and a certain volume of PBS (to achieve the total volume of the reaction mixture 2 mL
after adding the enzyme) were placed. The enzymatic reaction was started by adding the enzyme.
The dependence of absorbance (λ = 412 nm) on time was observed for 70 s (reference solution was the
same as for uninhibited reaction), and then the reaction rate (vi) was calculated. For determination
of IC50 values, twelve different concentrations of inhibitor were used and each measurement was
performed in triplicate at least. Finally, the dependence of v0/vi on the concentration of the inhibitor
was determined, and IC50 was calculated from the obtained equation of the regression curve for y = 2
(coming out from the definition of IC50) [67]. The obtained results are summarized in Table 1.
3.4. Comparative Molecular Surface Analysis
A self-organizing neural network (SOM) is comprised of a single layer of neurons typically
arranged as a hexagonal or rectangular array of nodes using the unsupervised learning rules initially
proposed by Kohonen. The 2D topology of the neural grid with the defined winning and neighborhood
distances between individual neurons directly specifies the mutual relations between the neurons.
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The presented multidimensional input vector xs = (xs1, . . . , xsm) is distributed between neurons
according to the similarity/correlation weight criteria, where similar inputs are located in the same or
proximal nodes. A classical competitive Kohonen (KNN) approach relies on the comparison of the
input vector with the corresponding multi-element weight vectors wj = (wj1, . . . , wjm) that describe
each neuron in order to select the winning one (outC)
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where j = 1, . . . , n refers to a particular neuron, n refers to a number of neurons, m is the number of
weights per neuron and s indicates a particular input. Contrary to “winner takes all”, in the “winner
takes most” methodology, the w ights of the winning neuron and its neighbors are then modified to
resemble and subsequently attract similar input vectors. While the next input vector is being presented
to the network, the entire procedure is repeated.
In fa t, the self-org izing eural m pping is considered as a nonlinear projection tool, which
reduces the dimensionality of the input object, e.g., converts 3D objects to 2D, while maintaining
the topological relationships between input and output data. Additionally, the trained network can
be employed for the projections of the specified molecular property prescribed to the input vector
with the generation of the color-coded clustering planar pattern called a feature map. Consequently,
the SOM algorithm was used to generate an electrostatic potential map as a 2D topographic pattern
receiving input signals from points sampled randomly at the molecular surface [68]. In a such
application, the specification of the closest neighbor and then projection of signals into this particular
neuron is based on the comparison of each 3D input vector consisting of x, y, and z coordinates with
a three-element weight vector describing each neuron. The shape of the certain molecular surface
(template) encoded in the weights of the trained Kohonen network can be used for processing signals
coming from the surface of other molecule(s) (counter-template) providing a series of comparative
SOM maps to compare/contrast the superimposed molecular geometry.
The implementation of the SOM for the classification, visualization and compression of the
structural data has been widely reported, in particular for 2D mapping of the electrostatic potential on
3D molecular surfaces or partial atomic charges for atomic molecular representation [69].
3.5. PLS Analysis
The partial least squares (PLS) method expresses the relation between the variable y and a set of
predictors X in the form represented by the following Equation:
y = X × b + e (2)
where b is the vector of the regression coefficients and e is the vector of the errors. Generally, PLS
models are constructed for centered/autoscaled data, and their complexity is estimated using, e.g.,
the leave-one-out cross-validation (LOO-CV) procedure. In the LOO-CV, one repeats the calibration
process m times, each time treating the i-th left-out object as the prediction object. The dependent
variable for each left-out object is calculated on the basis of the model with one, two, three, etc. factors.
The root-mean-square error of CV for the model with j factors is defined as:
RMSECVj =
√
∑mi (obsi − predi,j)2
m
(3)
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where obs denotes the observed value of a dependent variable; pred is the predicted value of a dependent
variable; and i refers to the object index, which ranges from 1 to m. A model with k factors, for which
RMSECV reaches a minimum, is considered as the optimal one. The cross-validated q2CV is calculated as:
q2CV = 1−
∑mi (obsi − predi)2
∑mi (obsi −mean(absi))2
(4)
where obs is the observed value; pred is the predicted value; mean is the mean value of obs; and i refers




∑i (obsi − predi)2
m− k− 1 (5)
where m is the number of objects and k is the number of the PLS factors in the model.
The quality of external predictions was measured using the standard deviation of error of
prediction (SDEP) and q2test parameter, which are defined respectively as:
SDEP =
√
∑ni (predi − obsi)2
n
(6)
q2test = 1− ∑
n
i (obsi − predi)2
∑ni (obsi −mean(obsi))2
(7)
where n is the number of objects in a test set.
3.6. Iterative PLS-Based Variable Elimination
Redundant variables may influence a model and increase its complexity; therefore, the reduction
in the number of variables facilitates the interpretation of the model considerably. To find only reliable
variables that significantly contribute to the regression model, the modified PLS procedure with
uninformative variable elimination (UVE-PLS) as well as its modification, namely, iterative variable
elimination (IVE-PLS) can be applied successfully [70]. The original UVE-PLS algorithm, developed
by Centner et al., analyzes the stability of regression coefficients expressed as the mean(b)/s(b) ratio,
where s(b) represents the standard deviation of the regression coefficient b that is calculated by the
PLS method [71]. Instead of a single step UVE-PLS procedure, we previously proposed an iterative
algorithm based on the abs(mean(b)/s(b)) criterion to identify the variables to be eliminated. Basically,
the entire procedure consists of the following steps: (i) standard PLS analysis with LOO–CV to
assess the performance of the PLS model (q2CV); (ii) elimination of the matrix column with the lowest
abs(mean(b)/std(b)) value; (iii) standard PLS analysis of the new matrix without the column cancelled
in Step (ii); and (iv) recurrent repetition of Steps i–iii to maximize the LOO q2CV parameter.
3.7. PCA Analysis
The mapping of the molecular diversity forming the “infinite” chemical space (CS) into
the corresponding biological or property space generally requires multi-dimensional descriptor
representations. A specified molecule might be represented by a set of structural (S) and
physicochemical (P) properties organized in a vector, which represents an object in the CS.
The molecular distribution of the empirically (FCS) and virtually (VCS) generated compounds might be
graphically investigated using, e.g., a linear projection procedure called Principal Component Analysis
(PCA). PCA is a projection method that is designed to model multivariate data with a relatively small
number of so-called principal components. PCs are constructed as a linear combination of original
variables to maximize the description of data variance. The PCA model decomposes information
contained in a data matrix into the principal component scores and loadings.
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The score matrix contains information about any similarities among the data objects, while the
loading matrix allows the similarities among the variables and their roles in the construction of a given
principal component to be studied. The PCA model with f principal components for a data matrix X
can be presented as follows:
X = TPT + E (8)
where X is a data matrix with m objects and n variables, T is the score matrix with dimensions (m × f ),
PT is a transposed matrix of loadings with dimensions (f × n) and E is a matrix of the residual variance
(m × n) that is not explained by the first f principal components. The first few principal components
often capture interesting information about the data structure and uncover groups of objects, atypical
objects, etc., and also indicate the importance of the original data variables that contribute to the
observed structure. Therefore, visualization of scores and loadings and their further simultaneous
interpretation allow insight into a problem being studied to be gained [72].
3.8. Model Builder
The same laboratory was employed to specify all pharmacological data to eliminate potential
data noise that might have been introduced by pooling of data sets coming from various sources.
The in vitro AChE and BChE inhibition values (IC50) for the set of carbamate derivatives are listed
in Table 1. The distributions of the IC50 inhibition of carbamates 1–9c response in 12 equally spaced
containers (expressed in µM) are presented as histograms in Figure 1. The CACTVS/csed molecular
editor was used to specify the constitution of the respective compound models. The spatial geometry
of molecules was produced using the 3D generator CORINA. The (inter)change file format converter
OpenBabel was applied to convert the chemical data.
3.9. Molecular Modeling
The principal components of the modeling studies were conducted with the usage of the Sybyl–X
2.0/Certara software package (Certara, Princeton, NJ, USA) running on HP workstation with Debian
6.0 operating system. The standard Tripos force field (POWELL conjugate gradient algorithm) with
0.01 kcal/mol energy gradient convergence criterion and a distant dependent dielectric constant was
used to optimize the initial geometry of each compound (MAXMIN2 module). The Gasteiger–Hückel
procedure implemented in Sybyl for the electrostatic potential calculations was initially employed
to calculate the partial atomic charges. The trial alignments are typically defined to systematically
span the common scaffold of the analyzed compounds; therefore, one 15-ordered atom trial alignment
on molecule 1 was selected to cover the entire bonding topology in the maximal common structure
(MCS) by the atom FIT method based on the matching of atoms’ positions between the corresponding
atom pairs.
The SONNIA software was employed in CoMSA analysis to simulate 20 × 20 to 50 × 50 SOMs
with the winning distance varied in the range of 0.2–2.0. The Cartesian coordinates of the molecular
surfaces for superimposed molecules were proceeded by the SOM network to form a 2D map of
electrostatic potential. The structurally simplest analog 1 and molecules with the highest volume
descriptor 7a–c were used to form the template molecules. The output maps were subsequently
transformed to a 400- to 2500-element vector, which was processed by PLS method implemented in
the MATLAB programming environment.
The crystallographic structure of rhAChE was retrieved from the PDB repository (code 4EY6)
containing two amino acid chains and two galanthamine molecules. All heteroatoms, including
crystallographic waters, were extracted prior to the calculations. The ligand/protein structures were
prepared for the docking study in the pdbqt file format with Gasteiger charges calculated. During the
AutoDock simulation, various poses (default 9) were generated progressively from a single conformer
(energy optimized molecule) by applying a collection of preferred torsion angles to the rotatable bonds
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and evaluated by united-atom scoring function. All predicted binding modes, including the positions
of flexible side chains, were visualized using the VMD molecular graphics viewer.
3.10. In Vitro Cytotoxicity Assay
Human monocytic leukemia THP-1 cells were used for in vitro toxicity assay. Cells were obtained
from the European Collection of Cell Cultures (ECACC, Salisbury, UK) and routinely cultured in RPMI
1640 (Lonza, Verviers, Belgium) medium supplemented with 10% fetal bovine serum (FBS, Sigma),
2% L-glutamine, 1% penicillin and streptomycin (Lonza, Verviers, Belgium) at 37 ◦C with 5% CO2.
Cells were passaged at approximately one week intervals. The cytotoxicity of the compounds was
determined using a WST-1 assay kit (Roche Diagnostics, Mannheim, Germany) according to the
manufacturer’s instructions. The tested compounds were dissolved in DMSO and added in five
increasing concentrations (0.37, 1.1, 3.3, 10, and 30 µM) to the cell suspension in the culture RPMI
1640 medium. The maximum concentration of DMSO (Sigma) in the assays never exceeded 0.1%.
Subsequently, the cells were incubated for 24 h at 37 ◦C with 5% CO2. For WST-1 assays, cells
were seeded into 96-well plates (5 × 104 cells/well in 100 µL culture medium) in triplicate in
serum-free RPMI 1640 medium, and measurements were taken 24 h after the treatment with the
compounds. The median inhibition concentration values, IC50, were deduced through the production
of a dose-response curve. All data were evaluated using the GraphPad Prism 5.00 software (GraphPad
Software, San Diego, CA, USA). The results are summarized in Table 1.
4. Conclusions
Twenty-five benzyl (2S)-2-(arylcarbamoyl)pyrrolidine-1-carboxylates were synthesized and
characterized by IR, 1H, 13C and 19F NMR spectroscopy and HRMS as well as by optical rotations.
All compounds were tested for their in vitro ability to inhibit AChE and BChE. The selectivity index
of individual compounds to cholinesterases was determined. The screening of the cytotoxicity of all
the compounds was performed using human THP-1 cells, no significant changes in the viability of
cells were found up to concentration 30 µM. All the compounds showed rather moderate inhibitory
effect against AChE; benzyl (2S)-2-[(2-chlorophenyl)carbamoyl]pyrrolidine-1-carboxylate (5a)
(IC50 = 46.35 µM) was the most potent agent. On the other hand, benzyl (2S)-2-[(2-bromophenyl)-(6a)
and benzyl (2S)-2-[(4-bromophenyl)-carbamoyl]pyrrolidine-1-carboxylate (6c) expressed anti-BChE
activity (IC50 = 27.38 and 28.21 µM, respectively) comparable with that of rivastigmine. Compound 6a
and benzyl (2S)-2-[(2-hydroxyphenyl)carbamoyl]pyrrolidine-1-carboxylate (9a) demonstrated greater
selectivity to BChE. A comparative receptor-independent structure–inhibitory activity study of
proline-based carbamates as potential ChEIs is reported using the 3D neural methodology (CoMSA)
coupled with the IVE-PLS procedure. In fact, the ability of the fuzzy molecular representation
for a variety of training/test subset distribution was examined for a large populations models
generated using the stochastic SMV procedure. A systematic space inspection merged with the variable
elimination method produce the probabilistic pharmacophore geometry specifying descriptors that
have potentially the highest individual weightings to the observed AChE/BChE profiles. In silico
activity examination confirmed the significant qualitative difference in the inhibitory potency of
positional isomers reflected in the empirical data, especially for unfavorable para-substitution of
the phenyl ring. The visual investigation of a pharmacophore pattern gives a simplified picture of
regions that can be modified to modulate the desired BChE activity of the compound, providing
valuable hints for the property-oriented synthesis. Moreover, PCA analysis was employed to illustrate
the crucial variations in the inhibitory efficiency of the screened molecules with respect to their
structure, lipophilicity and activity profile. The performed molecular docking study demonstrated the
importance of the side chain R, especially for ortho-positioned analogs directly attached to the phenyl
ring. Moreover, a chlorine atom can contribute to hydrogen bond interactions with Tyr337 of chain
A as postulated in the case of the galanthamine binding mode. The inhibition activity profile for the
positional isomers can be partially explained by the possibility of hydrogen bond interactions in the
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catalytic core ranked according to ortho > meta > para substitution. It seems that an increase of bulkiness
at the para position of the phenyl ring is unfavorable for the inhibitory potency of the investigated
carbamates as observed also in the pharmacophore study.
Supplementary Materials: The supplementary material is available online.
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